Clinical studies indicated that the serum levels of irisin in patients with type 2 diabetes were 30% lower than the normal level, so the irisin becomes a highlight and anticipation in the treatment of type 2 diabetes (Choi et al., 2013; Crujeiras et al., 2014). The gene discussed is FNDC5; the disease is type 2 diabetes mellitus.